Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gilead Sciences (FRA:GIS) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Gilead Sciences Forward PE Ratio Related Terms
Gilead Sciences Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Gilead Sciences's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences Forward PE Ratio Chart
Gilead Sciences Annual Data
Trend
2015-12
2016-12
2017-12
2018-12
2019-12
2020-12
2021-12
2022-12
2023-12
2024-12
2025-12
Forward PE Ratio
7.96
6.64
10.60
9.29
9.22
8.96
10.32
12.48
11.17
12.69
14.21
Gilead Sciences Quarterly Data
2015-12
2016-03
2016-06
2016-09
2016-12
2017-03
2017-06
2017-09
2017-12
2018-03
2018-06
2018-09
2018-12
2019-03
2019-06
2019-09
2019-12
2020-03
2020-06
2020-09
2020-12
2021-03
2021-06
2021-09
2021-12
2022-03
2022-06
2022-09
2022-12
2023-03
2023-06
2023-09
2023-12
2024-03
2024-06
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
7.96
7.20
6.86
6.72
6.64
8.64
8.78
10.72
10.60
11.35
11.21
11.06
9.29
9.89
9.97
8.94
9.22
11.81
12.09
9.02
8.96
9.04
9.29
10.62
10.32
9.00
9.61
9.67
12.48
12.17
11.17
10.27
11.17
10.38
17.99
11.56
12.69
13.48
13.03
12.90
14.21
16.15
FRA:GIS vs PFE, BMY, AMGN: Forward PE Ratio Comparison
For the Drug Manufacturers - General subindustry, Gilead Sciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Gilead Sciences (FRA:GIS) has a Forward PE Ratio of 41.06 as of Aug. 02, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Gilead Sciences and its competitors. According to the industry distribution chart, Gilead Sciences ranks #346 out of 409 companies in the Drug Manufacturers industry, placing it in the top 84.6%.
Is Gilead Sciences' Forward PE Ratio too high?
Gilead Sciences' current Forward PE Ratio is 41.06. The Drug Manufacturers industry median Forward PE Ratio is 17.47. Gilead Sciences' value of 41.06 is 135% above this industry median. Based on the distribution chart, Gilead Sciences ranks #346 out of 409 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Gilead Sciences has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Forward PE Ratio compare to PFE and BMY?
According to the Drug Manufacturers industry distribution chart, Gilead Sciences ranks #346 out of 409 companies for Forward PE Ratio. This places Gilead Sciences in the lower half of its industry. The industry median Forward PE Ratio is 17.47. Gilead Sciences' value of 41.06 is 135% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.47, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gilead Sciences's current Forward PE Ratio of 41.06 is 135% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Gilead Sciences and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gilead Sciences's current Forward PE Ratio is 41.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €83.55, compared to a current price of €113.04 — trading 35.3% above its estimated fair value. The current Forward PE Ratio is 41.06 and 135% above the Drug Manufacturers industry median of 17.47. Gilead Sciences' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current Forward PE Ratio is 41.06 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gilead Sciences (FRA:GIS) Overvalued in 2026?
Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued.
The current stock price of €113.04 is trading 35.3% above its estimated GF Value™ of €83.55.
GuruFocus considers Gilead Sciences to be Significantly Overvalued.
Key valuation signals for FRA:GIS:
Forward PE Ratio: 41.06
GF Value™: €83.55 vs. price of €113.04 (35.3% above fair value)
Industry Position: 135% above the Drug Manufacturers median (#346 of 409)
No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
75GF Score
Get the complete analysis for FRA:GIS
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GIS has been successfully added to your 
